Illinois is currently home to 2672 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Bridging the Health Disparities Gap in Decision-Making Among Limited English Proficient (LEP) Patients with Pelvic Floor Disorders
NCT05871268
Recruiting
Understanding a patient's decision-making preference can help physicians meet their expectations and may increase patient satisfaction with the decision-making process.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/03/2025
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Preferred Level of Involvement in Decision Making LEP Patients
Register for Updates
Urinary Microbiome Changes Following Administration of 500 Mg of NDS-446 in Women with Dry OAB At 12 Weeks
NCT05557279
Recruiting
The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/03/2025
Locations: Loyola Medical Center, Maywood, Illinois
Conditions: Overactive Bladder
Register for Updates
Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)
NCT04827420
Recruiting
The over-arching research question is: Does message (Advise) and referral approach (Refer) influence a patient's willingness to "opt-in" to receive a call from an Illinois Tobacco Quitline (ITQL) smoking cessation coach in patients at MSHC. Primary UH3 study aim: Compare the effect of the portal-delivered Choice message (Arm 1) to the Information-only message (Arm 3) on linkage to the Illinois Tobacco Quitline (i.e., spoke to a Quitline coach). Secondary UH3 aims are to: Examine the reach of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Tobacco Use Cessation
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Chicago, Illinois
Conditions: Neoplasms
Register for Updates
Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Asthma Allergy Center of Chicago, Chicago, Illinois
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT06035744
Recruiting
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Advanced Solid Tumor
Register for Updates
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
NCT05873634
Recruiting
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/27/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
NCT05494593
Recruiting
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic... Read More
Gender:
MALE
Ages:
6 years and below
Trial Updated:
02/27/2025
Locations: Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois
Conditions: Mucopolysaccharidosis (MPS), Hunter Syndrome
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Rush University, Chicago, Illinois
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: OSF Saint Joseph Medical Center, Bloomington, Illinois
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Nasal Antisepsis for C. Auris Prevention
NCT06282510
Recruiting
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Candida Auris Infection, Colonization, Asymptomatic
Register for Updates